Fujirebio Diagnostics Inc. Company Profile

17:10 EDT 20th September 2018 | BioPortfolio

News Articles [321 Associated News Articles listed on BioPortfolio]

FDA approves Fujirebio's Lumipulse G B•R•A•H•M•S PCT assay

Fujirebio Diagnostics, a consolidated subsidiary of Miraca Holdings, has secured approval from the US Food and Drug Administration (FDA) for its Lumipulse G B•R•A•H•M•S procalcitonin (PCT) a...

Janssen gets rights to Fujirebio assay for use in Alzheimer's

Miraca Holdings’ Fujirebio Inc. licensed Janssen Pharmaceuticals Inc. rights to develop and commercialize an amyloid beta 42/40 ratio assay that will run on Fujirebio’s Lumipulse chemiluminescent ...

Fujirebio and Janssen Partner to Develop An Assay to Identify Patients that may Benefit from Janssen’s Investigational Alzheimer’s Disease Drug

MALVERN, Pa.–(BUSINESS WIRE)–Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fuji...

Fujirebio, Janssen sign deal to develop AMYLOID ß 42/40 RATIO assay

Miraca’s consolidated subsidiary Fujirebio has signed an agreement with US-based Janssen Pharmaceuticals for the development and commercialization of an AMYLOID β 42/40 RATIO assay.

Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay

Testing for Change in PCT Levels Assists with Antibiotic Stewardship and Risk Assessment Of Lower Respiratory Tract Infections and Sepsis Fujirebio Diagnostics, Inc., a...

Fujirebio Enters into Agreement with Janssen Pharmaceuticals to Develop and Commercialize AMYLOID β 42/40 RATIO Assay

Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the C...

Emosis, 5─Diagnostics ink exclusive distribution deal for Emo─test, HIT Confirm, in CE Mark─regulated countries

Emosis, a medical device company specialising in cytomolecular diagnostics of hemostasis disorders, and 5─Diagnostics (5─D), a worldwide distributor for haemostasis products and in─vitro diagnos...

2018 Thermo Fisher: Market Shares and Competitive Position by Product and CountryPerformance, Capabilities, Goals and Strategies in the Global Diagnostics Industry [Report Updated: 01011970] Prices from USD $4250

This unique market intelligence report from VPGMarketResearch provides information not available from any other published source. The report includes diagnostics sales and market share estimates by pr...

Drugs and Medications [20 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [A.M. Home Diagnostics Inc. dba Healthline]


Cystografin dilute diatrizoate meglumine injection usp 18% [Bracco Diagnostics Inc.]

CYSTOGRAFIN DILUTE Diatrizoate Meglumine Injection USP 18%

Cystografin diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

CYSTOGRAFIN Diatrizoate Meglumine Injection USP 30%

Multihance [Bracco Diagnostics Inc]

These highlights do not include all the information needed to use MultiHance safely and effectively. See full prescribing information for MultiHance. MultiHance (gadobenate dimeglumine) injection Init...

Reno-30 diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

RENO-30 Diatrizoate Meglumine Injection USP 30%

PubMed Articles [189 Associated PubMed Articles listed on BioPortfolio]

Dizziness and vertigo associated with vestibular neuronitis: the approaches to the diagnostics and treatment.

This article is focused on the peculiar features of diagnostics and treatment of dizziness and vertigo in the patients presenting with vestibular neuronitis. The authors present the detailed overview ...

Statistical primer: checking model assumptions with regression diagnostics.

Regression modelling is an important statistical tool frequently utilized by cardiothoracic surgeons. However, these models-including linear, logistic and Cox proportional hazards regression-rely on c...

SwissFEL Aramis beamline photon diagnostics.

The SwissFEL Aramis beamline, covering the photon energies between 1.77 keV and 12.7 keV, features a suite of online photon diagnostics tools to help both users and FEL operators in analysing data...

Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.

The importance of medical imaging in the diagnosis and monitoring of cancer cannot be overstated. As personalized cancer treatments are gaining popularity, a need for more advanced imaging techniques ...

Is bronchoscopy always justified in diagnosis of haemoptysis?

Fiber-optic bronchoscopy (FOB) is commonly performed in the first line in diagnostic process of haemoptysis. However, lots of evidences suggest that in haemoptysis FOB do not always provide additional...

Clinical Trials [213 Associated Clinical Trials listed on BioPortfolio]

Differential Diagnostics of Etiology of Acute Infections

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB me...

Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobi...

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

The purpose of this study is to assess the performance of the HTLV Blot 2.4 from patients with the following conditions: infected with HTLV and neurological conditions with symptoms simila...

Non-Invasive Diagnostics of Small Renal Masses

NiSAR is a Ph.D. study and consists of three substudies. Renal cancer is one of the most deadly urologic malignancies and accounts for 900 new cases and 300 deaths per year. An increase in...

Companies [930 Associated Companies listed on BioPortfolio]

Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pi...

JFK Communications, Inc.

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and co...

Fujirebio Diagnostics,Inc

Formerly Certocor Diagnostics,Fujirebio Diagnostics,Inc.was acquired by ourparent company Fujirebio,Inc.of Tokyo,Japan in November 1998.

Gold Standard Diagnostics, Corp.

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, ...

Fujirebio Inc.

Founded in 1950, Fujirebio Inc. is an international leading diagnostic supplier, a part of Miraca Group, Japan’s leading healthcare group with its focus on clinical laborator...

More Information about "Fujirebio Diagnostics Inc." on BioPortfolio

We have published hundreds of Fujirebio Diagnostics Inc. news stories on BioPortfolio along with dozens of Fujirebio Diagnostics Inc. Clinical Trials and PubMed Articles about Fujirebio Diagnostics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fujirebio Diagnostics Inc. Companies in our database. You can also find out about relevant Fujirebio Diagnostics Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record